THERAPEUTIC CLASS

Lung Cancer Biomarkers

---

The molecular characterization of lung cancer has considerably changed the classification and treatment of these tumors, becoming an essential component of pathologic diagnosis and oncologic therapy decisions. Through the recognition of novel biomarkers, such as epidermal growth factor receptor mutations and anaplastic lymphoma kinase translocations, it has been possible to identify subsets of patients who benefit from targeted molecular therapies. The success of targeted anticancer therapies and new immunotherapy approaches has created a new paradigm of personalized therapy and has also led to accelerated development of new drugs for lung cancer treatment. This review focuses on clinically relevant cancer biomarkers as targets for therapy, as well as potential new targets for drug development

---

Availability

Detail Information

Series Title

-

Call Number

-

Publisher

: .,

Collation

-

Language

English

ISBN/ISSN

-

Classification

NONE

Content Type

-

Media Type

-

Carrier Type

-

Edition

-

Subject(s)

Oncology
Docetaxel
Carboplatin
Cisplatin
Fonkogem

Specific Detail Info

Hematol Oncol Clin North Am. 2017 February ; 31(1): 13–29

Statement of Responsibility

-

Other version/related

File Attachment

Comments

---

You must be logged in to post a comment